focus -WSS

focus

author：entertainment 2025-10-02 10:38:40 - browse：23294

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Medicare drug price negotiation continues, as pharma counteroffers

WSS

The untold story of TV’s first prescription drug ad

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

The SUPPORT Act is critical to fighting the opioid crisis

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

For AI in health care standards, federal regulators join with industry group

Generative AI mines health records to identify patients’ social needs

hotspot

focus

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

New England Journal of Medicine addresses racist history, slavery

Hollywood unions extend contract negotiations for actors

Longer MASH drug regimen improved liver, Akero study finds

Medicare details structure of new drug price negotiation program

Immune cells and nerve overgrowth may explain recurring UTI pain

Supreme Court strikes down use of affirmative action

Ozempic has benefits for kidney disease as well as diabetes

How one medical school became remarkably diverse

Ancient Greek ideas underpin modern concepts of pregnancy

hotspot

HHS names first

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Fauci’s Covid grilling leads GOP to weigh foreign research rules

He's 19 months old and has one of the world’s rarest diseases

Health and fitness trackers are measuring the wrong things

New England Journal of Medicine addresses racist history, slavery

leisure time

hotspot

Wikipedia

hotspot